Back to search results

Observational Study on Hypoxia Imaging for Head and Neck Cancer

This study is looking at new ways to image (take pictures of) head and neck cancer to better understand how it responds to treatment. Researchers are using advanced MRI (Magnetic Resonance Imaging) techniques to detect "hypoxia" (areas of low oxygen in the tumor), which can make cancer harder to treat. You might be able to join if you have newly diagnosed head and neck squamous cell carcinoma (HNSCC) and are planning to have chemoradiotherapy or surgery. The study will compare these new MRI images with a standard imaging test called [18F]MISO-PET/CT to see how well they match up. The goal is to find better ways to personalize treatment plans for head and neck cancer patients. This is an observational study, meaning researchers will be collecting information without giving you a specific treatment.

Study design
This is an observational study involving 20 participants. Researchers will collect information without assigning a specific treatment.
What's involved
You will undergo [18F]MISO-PET/CT imaging as a standard reference. The study will also involve multiparametric MR (MPMR) imaging.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, correlation of hypoxia volume, will be measured at 1 year. Treatment response will be assessed by 3 months post CRT FDG-PET.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06108089

Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment

Recruiting
Not specifiedAges 18+Observational
University of Utah
~20 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:[18F]MISO-PET/CT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The correlation of hypoxia volume between hypoxia MR and F18-FMISO PET
Measured over 1 year

Conditions

Head and Neck Cancer
Hypoxia
Magnetic Resonance Imaging
Cancer Neck

Explore related trials

Head and Neck Squamous Cell Carcinoma

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Yoshimi Anzai, M.D. · PRINCIPAL_INVESTIGATOR · University of Utah

Who to contact

Olivia Pratt
[email protected]
(801)585-6142
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Newly diagnosed HNSCC (head and neck squamous cell carcinoma) by biopsy or fine needle aspiration originating from the oral cavity, larynx, hypopharynx, nasopharynx, and oropharynx
Patients are scheduled to undergo chemoradiotherapy or surgery
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion

Pregnant patients
Patients with claustrophobia
Patients with pacemaker, spinal stimulator, or cochlear implant that are not MR compatible or any other metallic objects in the body
Patients who had been treated for HNC, either surgery, radiation therapy, or chemotherapy
Patients with thyroid, skin, sinonasal, and salivary gland cancer.
Abnormal kidney function defined as estimated glomerular filtration rate (eGRF) \< 30 mL/min/1.73 m2
Patients with uncontrolled diabetes
Patients who obtained outside FDG-PET/CT prior to initial treatment

What this trial measures

  • The correlation of hypoxia volume between hypoxia MR and F18-FMISO PET1 year

    the correlation of the percentages of hypoxia volume on hypoxia MR and F18-FMISO PET as the standard references